Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | MDH2 | P40926 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393420 | 0.82 | PARP1 (0.52) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL3793445 | 0.82 | PARP1 (0.47) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL393756 | 0.82 | PARP1 (0.51) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL13936706 | 0.82 | PARP1 (0.51) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL2274667 | 0.81 | PARP1 (0.46) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL3590838 | 0.81 | PARP1 (0.50) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL3939786 | 0.81 | PARP1 (0.50) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL14253832 | 0.81 | PARP1 (0.50) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL3247853 | 0.80 | PARP1 (0.49) | PARP1KIF11GSK3BCCNB2CDK1 | |
| SCHEMBL2276592 | 0.80 | PARP1 (0.44) | PARP1KIF11GSK3BCCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231668-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009086139-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086139-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, EIF2AK2, MAVS | PARP1 4122/4885KIF11 1657/4885GSK3B 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.